Multi-aspect candidates for repositioning: Data fusion methods using heterogeneous information sources

Current Medicinal Chemistry

Volumn 20, Issue 1, 2013, Pages 95-107

  Arany, A ^a,b   Bolgar B ^b   Balogh, B ^a   Antal, P ^b   Matyus P ^a,c  

^a University Semmelweis   (Hungary)

^b BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

^c PÁZMÁNY PÉTER CATHOLIC UNIVERSITY   (Hungary)

Author keywords

Data fusion; Drug repositioning; In silico drug discovery; Kernel fusion; Side effect; Similarity search; Support vector machine

Indexed keywords

ANTINEOPLASTIC AGENT; CALCINEURIN INHIBITOR; DERMATOLOGICAL AGENT; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG INFORMATION; DRUG REPOSITIONING; GOLD STANDARD; INFORMATION SYSTEM; KERNEL BASED APPROACH; STRUCTURE ACTIVITY RELATION; SUPPORT VECTOR MACHINE;

DRUG DISCOVERY; DRUG REPOSITIONING; HUMANS; INFORMATION STORAGE AND RETRIEVAL; SUPPORT VECTOR MACHINES;

EID: 84872958472     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673130110     Document Type: Article

References (83)

1. Li, Y.Y.; Jones, S.J. Drug repositioning for personalized medicine. Genome Med., 2012, 4, (27).
2. Sirota, M.; Dudley, J.T.; Kim, J.; Chiang, A.P.; Morgan, A.A.; Sweet-Cordero, A.; Sage, J.; Butte, A.J. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med., 2011, 3, 96ra77.
3. Ashburn, T.; Thor, K. Drug repositioning: Identifying and developing new uses for existing drugs. Nat. Rev. Drug Discovery, 2004, 3, 673-683.
4. Willett, P.; Barnard, J.; Downs, G. Chemical similarity searching. J. Chem. Inf. Model., 1998, 38, 983-996.
5. Eckert, H.; Bajorath, J. Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. Drug Discovery Today, 2007, 12, 225-233.
6. Chen, B.; Mueller, C.; Willett, P. Combination rules for group fusion in similarity-based virtual screening. Mol. Inf., 2010, 29, 533-541.
7. Keiser, M.; Roth, B.; Armbruster, B.; Ernsberger, P.; Irwin, J.; Shoichet, B. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol., 2007, 25, 197-206.
8. Willett, P. Enhancing the effectiveness of ligand-based virtual screening using data fusion. QSAR Comb. Sci., 2006, 25, 1143-1152.
9. Svensson, F.; Karlén, A.; Sköld, C. Virtual screening data fusion using both structure-and ligand-based methods. J. Chem. Inf. Model., 2011, 52, 225-232.
10. Dudley, J.; Deshpande, T.; Butte, A. Exploiting drug-disease relationships for computational drug repositioning. Briefings Bioinf., 2011, 12, 303-311.
11. Gottlieb, A.; Stein, G.; Ruppin, E.; Sharan, R. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol. Syst. Biol., 2011, 7.
12. Li, Y.; An, J.; Jones, S. A computational approach to finding novel targets for existing drugs. PLoS Comput. Biol., 2011, 7
13. Sirota, M.; Dudley, J.; Kim, J.; Chiang, A.; Morgan, A.; Sweet-Cordero, A.; Sage, J.; Butte, A. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med., 2011, 3
14. Swamidass, S. Mining small-molecule screens to repurpose drugs. Briefings Bioinf., 2011, 12, (4), 327-335.
15. Sardana, D.; Zhu, C.; Zhang, M.; Gudivada, R.; Yang, L.; Jegga, A. Drug repositioning for orphan diseases. Briefings Bioinf., 2011, 12, 346-356.
16. Paolini, G.; Shapland, R.; van Hoorn, W.; Mason, J.; Hopkins, A. Global mapping of pharmacological space. Nature Biotechnol., 2006, 24, 805-815.
17. Hopkins, A. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol., 2008, 4, 682-690.
18. Keiser, M.; Setola, V.; Irwin, J.; Laggner, C.; Abbas, A.; Hufeisen, S.; Jensen, N.; Kuijer, M.; Matos, R.; Tran, T.; Whaley, R.; Glennon, R.; Hert, J.; Thomas, K.; Edwards, D.; Shoichet, B.; Roth, B. Predicting new molecular targets for known drugs. Nature, 2009, 462, 175-U148.
19. von Eichborn, J.; Murgueitio, M.; Dunkel, M.; Koerner, S.; Bourne, P.; Preissner, R. PROMISCUOUS: a database for network-based drugrepositioning. Nucleic Acids Res., 2011, 39, D1060-D1066.
20. Schadt, E.; Friend, S.; Shaywitz, D. OPINION A network view of disease and compound screening. Nat. Rev. Drug Discovery, 2009, 8, 286-295.
21. Gillam, M.; Feied, C.; Handler, J.; Moody, E.; Shneiderman, B.; Plaisant, C.; Smith, M.; Dickason, J. In The Fourth Paradigm. Hey, T.; Tansley, S.; Tolle, K.M., Eds.; Microsoft Research, 2009, 57-64.
22. Walter, C.; Shah, A.; Nolte, M. Strategies to support drug discovery through integration of systems and data. Drug Discovery Today, 2007, 12, 634-639.
23. Goh, K.; Cusick, M.; Valle, D.; Childs, B.; Vidal, M.; Barabasi, A. The human disease network. Proc. Natl. Acad. Sci. M. S. A, 2007, 104, 8685-8690.
24. Barabasi, A.; Oltvai, Z. Network biology: Understanding the cell's functional organization. Nat. Rev. Genet., 2004, 5, 101-U115.
25. Lamb, J. Innovation -The Connectivity Map: a new tool for biomedical research. Nat. Rev. Cancer, 2007, 7, 54-60.
26. Lamb, J.; Crawford, E.; Peck, D.; Modell, J.; Blat, I.; Wrobel, M.; Lerner, J.; Brunet, J.; Subramanian, A.; Ross, K.; Reich, M.; Hieronymus, H.; Wei, G.; Armstrong, S.; Haggarty, S.; Clemons, P.; Wei, R.; Carr, S.; Lander, E.; Golub, T. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science, 2006, 313, 1929-1935.
27. Andersson, C.; Fryknas, M.; Rickardson, L.; Larsson, R.; Isaksson, A.; Gustafsson, M. In vitro drug sensitivity-gene expression correlations involve a tissue of origin dependency. J. Chem. Inf. Model., 2007, 47, 239-248.
28. Hu, G.; Agarwal, P. Human disease-drug network based on genomic expression profiles. PLoS One, 2009, 4, (8).
29. Qu, X.; Gudivada, R.; Jegga, A.; Neumann, E.; Aronow, B. Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships. BMC Bioinf., 2009, 10.
30. Iorio, F.; Bosotti, R.; Scacheri, E.; Belcastro, V.; Mithbaokar, P.; Ferriero, R.; Murino, L.; Tagliaferri, R.; Brunetti-Pierri, N.; Isacchi, A.; di Bernardo, D. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl. Acad. Sci. M. S. A., 2010, 107, 14621-14626.
31. Campillos, M.; Kuhn, M.; Gavin, A.; Jensen, L.; Bork, P. Drug target identification using side-effect similarity. Science, 2008, 321, 263-266.
32. Nelson, S.; Powell, T.; Huhmpreys, B.The unified medical language system (umls) project 2010.
33. Gunther, S.; Kuhn, M.; Dunkel, M.; Campillos, M.; Senger, C.; Petsalaki, E.; Ahmed, J.; Urdiales, E.; Gewiess, A.; Jensen, L.; Schneider, R.; Skoblo, R.; Russell, R.; Bourne, P.; Bork, P.; Preissner, R. SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res., 2008, 36, D919-D922.
34. Wishart, D.; Knox, C.; Guo, A.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res., 2008, 36, D901-D906.
35. NIMH Psychoactive Drug Screening Program Ki Database -http://pdsp.med. unc.edu/kidb.php.
36. Kuhn, M.; Campillos, M.; Letunic, I.; Jensen, L.; Bork, P. A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol., 2010, 6, -.
37. Henrickson, J.; Johnson, M.; Maggiori, G. Concepts and applications of molecular similarity. Science, 1991, 252, 1189-1189.
38. Kubinyi, H. Similarity and dissimilarity: A medicinal chemist's view. Perspect. Drug Discovery Des., 1998, 9-11, 225-252.
39. Whittle, M.; Gillet, V.; Willett, P.; Loesel, J. Analysis of data fusion methods in virtual screening: Similarity and group fusion. J. Chem. Inf. Model., 2006, 46, 2206-2219.
40. Whittle, M.; Gillet, V.; Willett, P. Analysis of data fusion methods in virtual screening: Theoretical model. J. Chem. Inf. Model., 2006, 46, 2193-2205.
41. Salim, N.; Holliday, J.; Willett, P. Combination of fingerprint-based similarity coefficients using data fusion. J. Chem. Inf. Model., 2003, 43, 435-442.
42. Ginn, C.; Willett, P.; Bradshaw, J. Combination of molecular similarity measures using data fusion. Perspect. Drug Discovery Des., 2000, 20, 1-16.
43. Chen, B.; Harrison, R.; Papadatos, G.; Willett, P.; Wood, D.; Lewell, X.; Greenidge, P.; Stiefl, N. Evaluation of machine-learning methods for ligandbased virtual screening. J. Comput.-Aided Mol. Des., 2007, 21, 53-62.
44. Ginn, C.; Turner, D.; Willett, P.; Ferguson, A.; Heritage, T. Similarity searching in files of three-dimensional chemical structures: Evaluation of the EVA descriptor and combination of rankings using data fusion. J. Chem. Inf. Model., 1997, 37, 23-37.
45. Chiang, A.; Butte, A. Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. Clin. Pharmacol. Ther., 2009, 86, 507-510.
46. Feher, M. Consensus scoring for protein-ligand interactions. Drug Discovery Today, 2006, 11, 421-428.
47. Kovesdi, I.; Dominguez-Rodriguez, M.; Orfi, L.; Naray-Szabo, G.; Varro, A.; Papp, J.; Matyus, P. Application of neural networks in structure-activity relationships. Med. Res. Rev., 1999, 19, 249-269.
48. Chen, B.; Harrison, R.; Papadatos, G.; Willett, P.; Wood, D.; Lewell, X.; Greenidge, P.; Stiefl, N. Evaluation of machine-learning methods for ligandbased virtual screening. Journal of Computer-Aided Molecular Design, 2007, 21, 53-62.
49. Hert, J.; Willett, P.; Wilton, D.; Acklin, P.; Azzaoui, K.; Jacoby, E.; Schuffenhauer, A. New methods for ligand-based virtual screening: Use of data fusion and machine learning to enhance the effectiveness of similarity searching. J. Chem. Inf. Model., 2006, 46, 462-470.
50. Jorissen, R.; Gilson, M. Virtual screening of molecular databases using a Support Vector Machine. J. Chem. Inf. Model., 2005, 45, 549-561.
51. Warmuth, M.; Liao, J.; Ratsch, G.; Mathieson, M.; Putta, S.; Lemmen, C. Active learning with support vector machines in the drug discovery process. J. Chem. Inf. Model., 2003, 43, 667-673.
52. Burbidge, R.; Trotter, M.; Buxton, B.; Holden, S. Drug design by machine learning: support vector machines for pharmaceutical data analysis. Comput. Chem. (Oxford, M. K.), 2001, 26, 5-14.
53. Vapnik, V. An overview of statistical learning theory. Ieee Trans. Neural Netw., 1999, 10, 988-999.
54. Warmuth, M.; Ratsch, G.; Mathieson, M.; Liao, J.; Lemmen, C.; Dietterich, T.; Becker, S.; Ghahramani, Z. Active learning in the drug discovery process. Adv. Neural Inf. Process. Syst., 2002, 14, 1449-1456.
55. Chow, S.; Chang, M. Adaptive design methods in clinical trials -a review. Orphanet Journal of Rare Diseases, 2008, 3.
56. Kapoor, A.; Greiner, R.; Gama, J.; Camacho, R.; Brazdil, P.; Jorge, A.; Torgo, L. Learning and classifying under hard budgets. Machine Learning: Ecml 2005, Proceedings, 2005, 3720, 170-181.
57. Pavlidis, P.; Weston, J.; Cai, J.; Noble, W. Learning gene functional classifications from multiple data types. J. Comput. Biol., 2002, 9, 401-411.
58. Lanckriet, G.; De Bie, T.; Cristianini, N.; Jordan, M.; Noble, W. A statistical framework for genomic data fusion. Bioinformatics, 2004, 20, 2626-2635.
59. Lanckriet, G.; Deng, M.; Cristianini, N.; Jordan, M.; Noble, W.; Altman, R.; Dunker, A.; Hunter, L.; Jung, T.; Klein, T. Kernel-based data fusion and its application to protein function prediction in yeast. Pacific Symposium on Biocomputing 2004, 2003, 300-311.
60. Rakotomamonjy, A.; Bach, F.; Canu, S.; Grandvalet, Y. SimpleMK.L. J. Mach. Learn. Res., 2008, 9, 2491-2521.
61. Tax, D.; Duin, R. Support vector data description. Mach. Learn., 2004, 54, 45-66.
62. Tax, D.; Duin, R. Support vector domain description. Pattern Recognit. Lett., 1999, 20, 1191-1199.
63. Moya, M.; Hush, D. Network constraints and multi-objective optimization for one-class classification. Neural Networks, 1996, 9, 463-474.
64. Schölkopf, B.; Platt, J.; Shawe-Taylor, J.; Smola, A.; Williamson, R. Estimating the support of a high-dimensional distribution. Neural Comput., 2001, 13, 1443-1471.
65. Fechner, N.; Jahn, A.; Hinselmann, G.; Zell, A. Estimation of the applicability domain of kernel-based machine learning models for virtual screening. J. Cheminf., 2010, 2, 2.
66. Wang, Y.; Zhang, C.; Deng, N.; Wang, Y. Kernel-based data fusion improves the drug-protein interaction prediction. Comput. Biol. Chem., 2011, 35, 353-362.
67. De Bie, T.; Tranchevent, L.; Van Oeffelen, L.; Moreau, Y. Kernel-based data fusion for gene prioritization. Bioinformatics, 2007, 23, I125-I132.
68. Tranchevent, L.; Capdevila, F.; Nitsch, D.; De Moor, B.; De Causmaecker, P.; Moreau, Y. A guide to web tools to prioritize candidate genes. Briefings Bioinf., 2011, 12, 22-32.
69. Dailymed current medication information -http://dailymed.nlm.nih.gov/ dailymed/.
70. Baeza-Yates, R.; B., R.-.N. Modern Information Retrieval. ACM Press: New York, 1999.
71. Vishwanathan, S.V.N.; Z. Sun, N.T.-.A.; Varma, M. In Advances in Neural Information Processing Systems: Vancouver, B. C., Canada, 2010.
72. Hand, D.J. Construction and Assessment of Classification Rules. Wiley & Sons: Chichester, 1997.
73. Bock, H.-.H.; Hand, D.J. Construction and Assessment of Classification Rules. Stat. Med., 2001, 20, (2), 326-327.
74. Swamidass, S.; Azencott, C.; Daily, K.; Baldi, P. A CROC stronger than ROC: measuring, visualizing and optimizing early retrieval. Bioinformatics, 2010, 26, 1348-1356.
75. Agarwal, S.; Dugar, D.; Sengupta, S. Ranking Chemical Structures for Drug Discovery: A New Machine Learning Approach. J. Chem. Inf. Model., 2010, 50, 716-731.
76. Zhao, W.; Hevener, K.E.; White, S.W.; Lee, R.E.; Boyett, J.M. A statistical framework to evaluate virtual screening. BMC Bioinf., 2009, 10, 13.
77. Truchon, J.; Bayly, C. Evaluating virtual screening methods: Good and bad metrics for the "early recognition" problem. J. Chem. Inf. Model., 2007, 47, 488-508.
78. Toque, H.; Teixeira, C.; Priviero, F.; Morganti, R.; Antunes, E.; De Nucci, G. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br. J. Pharmacol., 2008, 154, 787-796.
79. Seto, S.; Bexis, S.; McCormick, P.; Docherty, J. Actions of thalidomide in producing vascular relaxations. Eur. J. Pharmacol., 2010, 644, 113-119.
80. Cataldi, M.; Gaudino, A.; Lariccia, V.; Russo, M.; Amoroso, S.; di Renzo, G.; Annunziato, L. Imatinib-mesylate blocks recombinant T-type calcium channels expressed in human embryonic kidney-293 cells by a protein tyrosine kinase-independent mechanism. J. Pharmacol. Exp. Ther., 2004, 309, 208-215.
81. Clouser, C.; Patterson, S.; Mansky, L. Exploiting Drug Repositioning for Discovery of a Novel HIV Combination Therapy. J. Virol., 2010, 84, 9301-9309.
82. Randhawa, P.; Farasati, N.; Huang, Y.; Mapara, M.; Shapiro, R. Viral Drug Sensitivity Testing Using Quantitative PCR Effect of Tyrosine Kinase Inhibitors on Polyomavirus BK Replication. Am. J. Clin. Pathol., 2010, 134, 916-920.
83. Yu, S.; Tranchevent, L.; De Moor, B.; Moreau, Y.; DeMoor, B. L(n)-norm Multiple Kernel Learning and Least Squares Support Vector Machines in Kernel-Based Data Fusion For Machine Learning: Methods and Applications in Bioinformatics and Text Mining, 2011, 345, 39-88.